PROJECT DETAILS
- Research Name Laboratory Quality Control
- Client Real Madrid C.F
- Category Pathology
- RESEARCH TYPE Medicine
- RESEARCH YEAR 2016
- Delivery Mode Stipulated Price
- Location USA
SEMDEXA (SP-102)
SEMDEXA (SP-102) On-Track to be the First Product Approved to Treat Sciatica.
SP-102 is a preservative free, surfactant free and particulate free viscous gel formulation of dexamethasone for sciatica (lumbosacral radicular pain).
Extended local effect provides durable pain relief and significant improvement in functioning from a single injection with rapid onset.
Improvement against placebo over 4 weeks and continued effect over 12 weeks with reduced use of rescue therapy.
Good safety profile for single and repeat injections.
Common epidural delivery by minimally invasive procedure conducted in outpatient pain clinics.
Stable at refrigerated temperature in a prefilled syringe.
Only non-opioid solution for Chronic Back pain
- Up to 90% of chronic pain patients receive opioids (Benyamin, ASIPP)
- Half of Rx sales for pain are opioids (Datamonitor 2016)
Increased Deaths from Opioid use
- From 2000 to 2015 more than half a million people died from drug overdoses. 91 Americans die every day from an opioid overdose. Approximately 33,000 Americans in 2015 died from opiates (CDC)
Time to Switch to Non-opioids
- Non-opioids likely more effective in back pain according to a study of sciatica patients, opioids appeared to have no significant effect on pain improvement compared to non-opioids (Lewis et al 2013)
Our Process
Being a top us private facility for any kind of scientific research, we are proud of the overall amount of work we`ve done so far. Excepteur sint occaecat cupidatat non dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco proident, sunt in culpa qui officia deserunt mollit anim id est laborum.